drugset / Trial / NCT03752294
A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
Phase 1
Withdrawn
University of Rhode Island
Alzheimer's Drug Discovery Foundation · collabBoehringer Ingelheim · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
A randomized-control, double-blind, multi-center, delayed-start, pilot trial evaluating the disease modifying effects of a 150mg once-a-day dose vs. placebo of dabigatran in men and women, between the ages of 50-85 years, confirmed with MCI probably due to AD and mild Alzheimer's Disease.
Timeline
- Start
- 2019-05
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dabigatran | Unknown | 150 mg | — |